Dr. Richard Whitlock, the principal investigator of the LAAOS III trial, emphasized that his preferred method to achieve left atrial appendage exclusion is surgical occlusion during cardiac surgery in patients with atrial fibrillation who are at risk of stroke.​

The LAAOS III trial demonstrated that prophylactic LAA occlusion during heart surgery significantly reduces the long-term risk of stroke in patients with AF. ​

Learn more about LAA exclusion to reduce stroke risk* at: <a href="https://lnkd.in/e3Sz5ifs&quot; target="_blank">https://lnkd.in/e3Sz5ifs</a&gt; ​

*Originating from the LAA​

<a href='https://www.linkedin.com/feed/hashtag/?keywords=CardiacSurgery&highligh…; target='_blank'>#CardiacSurgery</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=LAAE&highlightedUpdateU…; target='_blank'>#LAAE</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=ReduceStrokeRisk&highli…; target='_blank'>#ReduceStrokeRisk</a>​
​

Backed by over a decade of clinical evidence, LAAE is a Class IA recommendation from AHA, ACC &amp; STS.​

The AtriClip® FLEX-Mini™ is the newest, lowest-profile device in our full LAAE portfolio—designed for gold-standard care.​
​
Learn more: <a href="https://t.co/JEybEUFTho&quot; target="_blank">https://t.co/JEybEUFTho</a&gt;

<a href="https://twitter.com/hashtag/CardioTwitter?src=hashtag_click&quot; target="_blank">#CardioTwitter</a>

Designed for patients with long-standing persistent Afib, the EPi-Sense ST™ System is the only FDA-approved device for minimally invasive ablation therapy to treat LSPAF.​

Discover how EPi-Sense ST™ is helping address the most undertreated Afib population:

The AtriClip® FLEX-Mini™ delivers continuous closing pressure through easy one-handed, suture-less deployment for enhanced surgical control.​

Discover the lowest-profile surgical LAAE device: <a href="https://t.co/3PxTkDVSXP&quot; target="_blank">https://t.co/3PxTkDVSXP</a&gt; ​

<a href="https://twitter.com/hashtag/AtriClip?src=hashtag_click&quot; target="_blank">#AtriClip</a> <a href="https://twitter.com/hashtag/CardioTwitter?src=hashtag_click&quot; target="_blank">#CardioTwitter</a> <a href="https://twitter.com/hashtag/LAAE?src=hashtag_click&quot; target="_blank">#LAAE</a>

Thanks to <a href="https://twitter.com/hashtag/cryoNB?src=hashtag_click&quot; target="_blank">#cryoNB</a>, post-op recovery doesn’t have to be the same from one generation to the next. Watch Justin share how his uncle’s pleurodesis recovery made him nervous—until he experienced a much different, smoother transition back to everyday life.​

Learn more:

Congratulations to Dr. vasileios lozos and the team at General Hospital of Athens Hippocratio on completing their first case with the EnCompass® Clamp for surgical ablation!
“Simple, quick, and effective!” -  these were Dr. Lozo's first comments after using the device, marking an important milestone in advancing AF care in Greece. We are pleased to support clinical teams dedicated to improving patient outcomes through innovation.

<a href='https://www.linkedin.com/feed/hashtag/?keywords=Afib&highlightedUpdateU…; target='_blank'>#Afib</a>

In the DEEP Trial, 62.4% of patients with Advanced Afib* who underwent hybrid ablation combined with left atrial appendage exclusion using AtriClip® remained free from atrial arrhythmias** at 2 years follow-up.​

*Persistent or long-standing persistent Afib.​​
**Effectiveness was

Hear from cardiothoracic surgeon Dr. John Ofenloch as he shares his experience using the EnCompass® Clamp and what sets it apart in surgical ablation.​

Discover more about EnCompass: <a href="https://t.co/ZLdcc2BNY6&quot; target="_blank">https://t.co/ZLdcc2BNY6</a&gt; ​

<a href="https://twitter.com/hashtag/Ablation?src=hashtag_click&quot; target="_blank">#Ablation</a> <a href="https://twitter.com/hashtag/CardioTwitter?src=hashtag_click&quot; target="_blank">#CardioTwitter</a>

Enrollment is closed for the largest randomized trial in cardiac surgery! The LeAAPS Trial will follow 6,500 patients over 5 years to study whether AtriClip® devices for LAAE can reduce stroke risk in high-risk patients without a history of Afib. Learn more:

Discover new AF treatment techniques and enhance your learning at the 39th EACTS - European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen October 8-11. Dive into our high-quality program featuring a symposium and get hands-on training at our booth. Don't miss out!

Learn more about AtriCure, Inc. at <a href='https://www.linkedin.com/feed/hashtag/?keywords=EACTS2025&highlightedUp…; target='_blank'>#EACTS2025</a>: <a href="https://bit.ly/EACTS2025&quot; target="_blank">https://bit.ly/EACTS2025</a&gt;